A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.

NCT05361564 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Brigatinib

Sponsor

Yonsei University